Effects of Switching from Insulin Glargine 100 to Insulin Glargine 300 on Glycemic Control and Treatment Satisfaction In Japanese People with Type 1 and Type 2 Diabetes

抄録

Aims: To investigate how switching from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) affects glycemic control and treatment satisfaction in Japanese people with type 1 and 2 diabetes.

Methods: We enrolled 152 outpatients with diabetes (type 1, n = 29; type 2, n = 123) being treated with basal-bolus therapy (BBT; n = 95) or basal only using as insulin therapy (n = 57) with Gla-100 and switched them all to Gla-300. The dose of Gla-300 was initially the same as that of Gla-100 and was then titrated up. We investigated changes in hemoglobin A1c (HbA1c), body weight, glargine insulin dose over three months, and diabetes treatment satisfaction questionnaire scores over three months.

Results: Three months after patients had switched to Gla-300, HbA1c and body weight had not changed significantly. In the whole group, the basal dose of Gla-300 insulin was significantly higher than that of Gla-100 (14.2 ± 8.1 vs 13.7 ± 7.9 units, respectively; P < 0.001). Separate analyses of the BBT and Basal only groups showed that in both the BBT and the Basal only group, the basal insulin dose was significantly higher with Gla-300 than with Gla-100. Patient treatment satisfaction scores did not change significantly after switching to Gla-300. In the BBT group, hypoglycemia was less frequent with Gla-300.

Conclusions: HbA1c, body weight, and treatment satisfaction were similar with Gla-100 and Gla-300. In people treated with BBT, Gla-300 may be associated with less frequent hypoglycemic episodes.